HPV Type 16

Written By Zachary Webel

Introduction

Human papillomavirus type 16 (HPV16) is a double-stranded DNA virus with a circular genome of ~7.9 kb. It is the most prevalent high-risk HPV type, found in about 50% of cervical cancers (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic). The L1 gene of HPV16 encodes the major capsid protein, which is 1,596 nucleotides long and forms virus-like particles; it is the primary component of current HPV vaccines. Because of its importance and relative conservation, the L1 gene is commonly used for HPV genotyping and evolutionary studies. HPV16 exhibits multiple intratype variant lineages (e.g. European, Asian, African lineages), which differ by up to ~10% at the nucleotide level across the genome ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ) (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic). These variant lineages co-diverged with ancient human populations, reflecting HPV16’s long association with humans. Despite this genomic diversity, HPV16 is known to evolve very slowly, consistent with its use of high-fidelity host DNA polymerases for replication (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic). This report examines the yearly evolution of the HPV16 L1 gene, focusing on global mutation rates. We estimate the mutation (substitution) rate per site per year and use it to calculate the expected number of nucleotide changes in the full 1,596-bp L1 gene per year. We also discuss the range of reported mutation rates (upper and lower bounds) and then highlight any recent trends (2020–2025) in HPV16 L1 evolution, including whether mutation rates have changed or new evolutionary patterns have emerged in the era of genomic surveillance and vaccination.

Per-Site Mutation Rate: Global Estimates

HPV16 is generally characterized by an extremely low evolutionary rate, in line with other small double-stranded DNA viruses. Broad estimates for papillomavirus substitution rates range from roughly 5 × 10^–9 to 2 × 10^–8 nucleotide substitutions per site per year for coding regions (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic). In other words, each nucleotide in the L1 gene has on the order of 10^–8 chance of mutating and becoming fixed in the population each year. This rate is among the slowest observed in viruses, comparable to or only slightly higher than the mutation rates of animal genomes (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic). A frequently cited average for HPV is ~2 × 10^–8 substitutions/site/year, reflecting the high fidelity of host DNA polymerase and strong purifying selection in viral genomes (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic). Indeed, HPV’s replication error rate has been described as about 2×10^–8 per site-year (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic), meaning that on evolutionary timescales only a tiny fraction of sites change per year. Such slow rates align with the long-term co-divergence hypothesis (HPV16 lineages radiating over tens of thousands to millions of years with their human hosts). Consistent with this, analysis of HPV16 sequences shows there is insufficient temporal signal to measure evolution over short periods – for example, root-to-tip phylogenetic regression fails to detect a clear clock (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic). Experimental observations reinforce the stability: HPV16 genomes persisting in cell culture (W12 cell line) showed no detectable variation above 0.5% frequency over time (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic), and longitudinal studies in humans find little to no change in the viral sequence within a few years (see below).

Lower-bound estimates: The lowest end of reported mutation rates for papillomaviruses is on the order of 5×10^–9 per site-year (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic). Such a low rate would be consistent with strong purifying selection and long-term stasis. It implies that most years would pass with essentially zero change at any given nucleotide of the L1 gene. For instance, a rate of 5×10^–9 s/s/y is comparable to some estimates for mammalian nuclear DNA (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic) and reflects the extreme genetic stability of HPV16 in the absence of selective pressures.

Upper-bound estimates: Some studies using phylogenetic or epidemiological data have suggested higher substitution rates for HPV16, though still far below those of RNA viruses. When assuming neutrality in rapidly evolving regions or using phylogenetic dating, rates in the 10^–7 range have been proposed. For example, one analysis of papillomavirus non-coding regions (assumed to evolve neutrally) yielded a substitution rate around 4.5 × 10^–7 per site-year ( Human papillomavirus genomics: Understanding carcinogenicity - PMC ). Similarly, a phylogeographic study of HPV16, calibrating divergence with human migrations, estimated a mean rate on the order of 10^–7 (e.g. ~1.5 × 10^–7, with an upper credibility limit around 2.5 × 10^–7) substitutions/site/year (Dating the origin and dispersal of Human Papillomavirus type 16 on ...). These higher estimates likely capture the fastest plausible pace of HPV16 evolution under certain assumptions (e.g. if many mutations are neutral). It’s worth noting that even this “high” rate is still extremely slow in absolute terms. Moreover, short-term studies that reported extraordinarily high rates (on the order of 10^–4 or 10^–3) are now understood to be artifactual. For instance, an early analysis of L1 sequences from GenBank suggested ~3.94×10^–3 s/s/y ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ) – implying ~0.4% of sites changing per year – but this was likely skewed by sampling bias and unrecognized co-infections. Deeper investigation showed that such a rate would predict ~31 nucleotide substitutions in the ~8kb HPV16 genome per year, which is “unreasonably high” given that HPV16 has co-existed with humans for millennia and yet any two HPV16 isolates differ by at most ~10% (≈790 bp) ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ). The consensus in the field is that the true long-term evolutionary rate of HPV16 lies much lower, in the 10^–9–10^–7 per site-year range, with a best estimate near 10^–8 (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic) (Papillomaviruses | Evolution, Medicine, and Public Health | Oxford Academic). In summary, we will adopt ~5×10^–9 as a conservative lower bound and ~1×10^–7 as an upper bound for the L1 gene’s per-site yearly mutation rate, acknowledging that most estimates cluster closer to the lower end.

Expected Mutations per Year in the Full L1 Gene

Given the L1 gene length of 1,596 nucleotides, we can project how many mutations accumulate in this gene per year on average, using the above rates. This is simply the per-site rate multiplied by 1,596.

  • Lower-bound scenario (~5 × 10^–9 s/s/y): At 5×10^–9 per site-year, the entire L1 gene would accrue about 8.0 × 10^–6 substitutions per year (5×10^–9 × 1596 ≈ 7.98×10^–6). In practical terms, this is 0.000008 mutations per year in the L1 gene – an exceedingly small number. Another way to state this is roughly 1 substitution in the L1 gene every 125,000 years on average at this rate. Essentially, over human timescales of decades, the expected number of new mutations in L1 tends toward zero in this minimal-evolution scenario.

  • Mid-range consensus (~2 × 10^–8 s/s/y): Using a mid-range estimate of 2×10^–8 per site-year (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic), we get about 3.2 × 10^–5 substitutions per year in L1 (2×10^–8 × 1596 ≈ 3.19×10^–5). This translates to 0.000032 mutations per year in the full gene, or roughly 1 mutation every 31,000 years. Even at this “typical” rate, the accumulation of changes in L1 is glacially slow – consistent with the observation that HPV16 variant lineages differ by only a few percent despite diverging tens of thousands of years ago.

  • Upper-bound scenario (~1 × 10^–7 s/s/y): At the high end of plausible rates, say 1×10^–7 per site-year, the L1 gene would accumulate about 1.6 × 10^–4 substitutions per year (1×10^–7 × 1596 = 1.596×10^–4). This is 0.00016 mutations per year for the whole gene, or about 1 substitution every 6,250 years on average. Even under this faster estimate, L1 would still appear essentially stable on epidemiological timescales (no noticeable changes year-to-year). For an extreme comparison, if we take the flawed 3.94×10^–3 estimate mentioned earlier, it would imply ~6.3 mutations in L1 per year ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ) – which is clearly not observed in reality. Actual data from modern sequencing consistently show that such rapid change does not occur in circulating HPV16. Most differences between HPV16 isolates reflect ancient divergence rather than ongoing rapid mutation.

In summary, the expected number of new nucleotide mutations in the 1,596-bp L1 gene per year is far below one – on the order of 10^–5 (tens of thousands of years per mutation) under the most conservative estimates, and at most ~10^–4 (several thousand years per mutation) even with generous assumptions. This underscores that HPV16’s L1 gene is highly genetically stable year-to-year. Figure 1 illustrates the stability and distribution of L1 mutations globally, highlighting that only a handful of amino acid changes are found at appreciable frequency in worldwide HPV16 isolates, reflecting mutations accumulated over long periods rather than recent rapid evolution.

( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC ) Figure 1: High-level summary of common mutations in the HPV16 L1 and L2 capsid genes across global populations. Panel (A) shows the HPV16 L1 protein (505 amino acids) with major surface loop regions (DC, DE, EF, FG, HI loops) highlighted in blue. The seven high-frequency amino acid substitutions in L1 (H76Y, T176N, N181T, A266T, T353P, T389S, L474F) are indicated along with their prevalence in different regions (Latin America, North America, Europe, Asia). For example, T176N is present in 14% of Latin American isolates vs ~7% in Europe ( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC ). Notably, the most variable L1 positions (e.g. 176, 181, 266, 353, 389, 474) reach at most ~20–40% frequency in one region, and many loop regions (DC, DE) are almost invariant (<0.1% variability ( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC )). Panel (B) shows the L2 protein for comparison. This illustrates that HPV16’s capsid genes have very limited diversity, consistent with a low mutation rate and purifying selection (most populations share the same dominant amino acids at these positions).

Evolutionary Trends in 2020–2025

Recent research continues to support the notion that HPV16 evolves extremely slowly, with no detectable increase in mutation rate in the 2020–2025 period. A notable study deep-sequenced complete HPV16 genomes from women over time (up to 15 years apart) and found no measurable substitutions in the L1 gene or elsewhere in the genome within individual infections ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ) ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ). In the majority of cases, the exact same HPV16 sequence persisted in a person for years, with a median within-host substitution rate of 0 substitutions/site/year ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ). This indicates that, on a short timescale (a few years or even a decade), the L1 gene is effectively static in an ongoing infection. Any sporadic sequence differences observed were attributable to infection by a different HPV16 variant rather than true new mutations ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC ). These findings (published ~2019) have been reinforced post-2020 by improved genomic surveillance – larger datasets of HPV16 genomes show very limited temporal change. In other words, the intrinsic mutation rate of HPV16 L1 does not appear to be accelerating in recent years; it remains at the same low level determined by the virus’s biology (host DNA polymerase fidelity and long-term purifying selection).

Furthermore, high-throughput sequencing efforts have expanded the catalog of HPV16 global variant diversity without revealing any novel hyper-mutated strains. By 2020–2023, thousands of HPV16 genomes from around the world had been analyzed, yet the spectrum of L1 variation still falls within the known lineages and their defining mutations (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic). Figure 1 (above) encapsulates the key mutations found in L1: these few high-frequency amino acid substitutions were already known from earlier variant studies, and their regional frequencies in 2023 remain similar to historical data. For instance, substitutions like T176N or T353P are enriched in certain lineages (e.g. Asian or American variants) but still absent in others ( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC ). The geographic clustering of HPV16 L1 variants persists, reflecting lineage distributions rather than any new mutations spreading globally. In sum, the post-2020 genomic data confirm that HPV16’s L1 gene is under strong purifying constraint (e.g. key neutralizing antibody epitopes in the DE loop remain >99.9% conserved worldwide ( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC )) and that the virus’s evolutionary pace has not changed in the last few years.

Immune Pressure and Patterns in the Vaccine Era

One question of interest in 2020–2025 has been whether widespread HPV vaccination might impose new selective pressures on the L1 gene, potentially accelerating the emergence of escape mutants. HPV16 L1 is the target of neutralizing antibodies induced by vaccines, so any mutation that allows the virus to evade vaccine-derived immunity could theoretically be favored. However, current evidence indicates that no significant vaccine-driven evolution of HPV16 L1 has occurred as of 2025. Genomic comparisons between HPV16 infections in vaccinated vs. unvaccinated individuals show no new mutation patterns. A 2023 study sequenced portions of L1, E6, and the regulatory region from young women who had received the bivalent HPV16/18 vaccine versus those unvaccinated; it found that the same variant lineages (mainly sub-lineages A1/A2, the common European lineage) circulated in both groups, with no unique amino acid changes emerging in vaccinated hosts (Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity) (Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity). The frequency of known L1 polymorphisms (such as the T266A substitution in the capsid FG-loop) was similar in vaccinated and unvaccinated women, suggesting random distribution of variants rather than selection by vaccine immunity (Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity). In fact, in that study the only statistically notable difference was a single regulatory-region SNP being marginally more frequent in vaccinated individuals, and even that did not translate into an amino acid change in L1 (Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity). Overall, the detection of HPV16 in vaccinated people appears to be due to occasional exposure to circulating variants (which vaccination greatly reduces but does not completely eliminate), not due to novel vaccine-resistant mutants (Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity). Moreover, neutralization assays have shown that sera from vaccinated individuals can neutralize a broad panel of naturally occurring HPV16 L1 variants, implying that no variant has escaped vaccine coverage to date (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic) (Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization | The Journal of Infectious Diseases | Oxford Academic). Thus, from 2020 to 2025 we do not observe an accelerated L1 mutation rate or a directional shift in L1 gene evolution attributable to vaccination. The virus’s low mutation rate and the broad efficacy of the vaccine against known variants have so far prevented any “vaccine-escape” lineage of HPV16 from arising.

Notable Findings and Ongoing Evolutionary Patterns

While the overall mutation rate of HPV16 L1 remains low, recent studies have provided new insights into how and where mutations occur when they do arise. One notable pattern involves the host’s APOBEC3 enzymes, which are cytidine deaminases that can introduce hypermutation in viral DNA. Deep sequencing of HPV16 isolates has revealed that many infrequent within-host single-nucleotide variants bear the hallmark of APOBEC3-induced mutations (characteristic C→T or G→A changes in specific motifs). Intriguingly, such APOBEC-linked minor variants in L1 (and other genes) were found to be enriched in individuals who cleared the infection (controls) compared to those who developed persistent infections or cancer (cases) ( Human papillomavirus genomics: Understanding carcinogenicity - PMC ). This suggests APOBEC3 activity can occasionally mutate the HPV16 genome at random sites – effectively a host-driven mutational burst – which may cripple the virus and aid clearance. These mutations are typically not transmitted or fixed in the viral population (because they often reduce fitness), but they contribute to the genetic “noise” observed in viral genomes. The presence of APOBEC-mediated edits is a recent finding (highlighted in 2021–2023 studies) that adds nuance to our understanding of HPV16 evolution: it shows that even a slowly evolving virus can undergo episodic mutational events, although most such events do not become permanent. In evolutionary terms, APOBEC3 may act as a source of genetic variation that, while usually deleterious, could in rare cases generate variants that survive. However, as of 2025, there is no evidence that APOBEC-driven mutations have led to any new dominant HPV16 lineage – it mainly underscores the ongoing tug-of-war between host defense and viral genome integrity.

Another ongoing pattern is the maintenance of distinct HPV16 variant lineages and their associated L1 polymorphisms. Global surveillance in the past few years has better mapped which L1 mutations correspond to which lineages and regions. For example, mutations like T176N and N181T (in the EF loop of L1) are characteristic of certain non-European lineages and are observed at higher frequency in Latin America and Asia ( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC ). The T266A change (FG loop) is found more often in North American/European lineages ( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC ). Meanwhile, other regions of L1 (such as the immunodominant DE loop) remain almost completely conserved across all variants ( Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas - PMC ), reflecting strong functional constraints (these loops contain key neutralizing antibody epitopes). These observations were already known, but recent data have solidified them with larger sample sizes. Importantly, the relative frequencies of the variant lineages in the global population can change slowly with epidemiology (for instance, if one lineage is more common in a growing population). However, this is a change in prevalence of existing variants, not a change in the mutation rate. For instance, if vaccination preferentially reduces certain lineages (those more common in vaccinated regions), others might become a larger share of remaining infections – but that’s a population dynamic effect, not an accelerated mutation. As of 2025, the variant lineage distribution of HPV16 still largely correlates with historical patterns (e.g. African lineages more often found in Africa, Asian in East Asia, etc.), although increased travel and globalization mean all major variants can be found worldwide (The E6 gene polymorphism of Human papillomavirus 16 in relation ...). No new distinct L1 variant has appeared; rather, researchers are now able to track known sub-lineages with higher resolution.

In summary, the period from 2020 to 2025 has confirmed the remarkably slow yearly evolution of the HPV16 L1 gene. Both upper-bound and lower-bound estimates of the mutation rate remain in roughly the same ranges cited in earlier literature (10^–7 to 10^–9 per site-year). This corresponds to an expected <0.0001 mutations per year in the full L1 gene, meaning decades or centuries pass between single-nucleotide changes in this region under natural conditions. Post-2020 studies have not detected any acceleration in this rate; if anything, they underscore that short-term evolution is virtually nil (within-host sequences are identical over years ( No measurable substitution rate in the HPV16 genome in women with subsequent in situ or invasive cervical cancer: prospective population-based study - PMC )). The L1 gene’s variability is largely due to ancient diversification and is kept in check by functional constraints (capsid structure and antibody recognition) and the high fidelity of replication. New data in the 2020–2025 timeframe have highlighted patterns like APOBEC3-induced hypermutations and have thoroughly catalogued the existing L1 variant repertoire, but they do not suggest any fundamental change in how fast HPV16 mutates. Going forward, continued genomic surveillance – especially as HPV vaccination programs mature – will be important to detect any sign of adaptive change. For now, however, HPV16’s L1 gene evolution can be described as highly stable, with an expected mutation count per year so low that it is usually immeasurable in real time.

References

Zachary Webel
Previous

Zaire Ebolavirus
Next

Rotavirus A